Boundless Bio (BOLD) said late Friday it optimized its portfolio and streamlined operations, including a one-third reduction of its workforce to drive long-term value creation.

The company discontinued the monotherapy and combination arms of BBI-355 candidate in Potentiate clinical trial due to toxicity concerns and a narrow therapeutic index, according to the company.

Boundless will attempt clinical development by combining BBI-335 and ribonucleotide reductase inhibitor, BBI-825, for "synergistic" anti-tumor activity as a replication stress combination therapy, the company said, adding it would present scientific details backing this decision on May 27.

The company declared the BBI-940 development candidate for the novel Kinesin program, according to a statement.

The company noted that workforce reduction, optimized operations, and portfolio changes are expected to extend its cash runway into H1 2028.